Preparation method of paridone
By reacting compound B with SM2 under alkaline conditions and adding neutralization reaction steps, combining ethanol-water system crystallization and nitrogen replacement protection, the problem of high impurity content in pariperone raw materials is solved, achieving high purity and high harvest The preparation of the drug quality standards and industrial production requirements.
Patent Information
- Application Number
- CN202411063956.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-09-11
- Filing Date
- 2024-08-05
- Publication Date
- 2024-11-19
AI Technical Summary
The prior art is difficult to simultaneously reduce the content of process impurities SM2, impurities E, impurities F and impurities I in the pariperone raw materials, and there is a problem of solvent residue and burning residue exceeding the standard, which cannot meet the requirements of industrial production and drug quality standards.
Compound B reacts with compound SM2 under alkaline conditions, adds neutralization reaction steps, and is purified by ethanol-water system, combined with nitrogen replacement protection, controls crystallization temperature and time, inhibits the generation and growth of impurities, and avoids the use of toxic reduction. agent.
It significantly improves the yield and purity of pariperidone, reduces the content of multiple process impurities and degraded impurities, meets the quality standards of commercial large-scale production and drug registration management methods, and avoids solvent residues and heavy metal introduction.
Smart Images

Figure BDA0004978827010000011 
Figure BDA0004978827010000012 
Figure BDA0004978827010000013
Abstract
Description
Technical Field
[0001] The present invention belongs to the technical field of drug synthesis, and in particular relates to a method for preparing paliperidone. In addition, the present invention also relates to a method for reducing impurities in paliperidone raw materials. Background Art
[0002] Paliperidone is the major active metabolite of the atypical antipsychotic drug risperidone. In the liver, risperidone is mainly hydroxylated via the cytochrome (CYP) P4502D6 pathway to 9-hydroxyrisperidone, paliperidone, which has comparable pharmacological characteristics and potency to risperidone and a longer elimination half-life.
[0003] The structure of paliperidone is shown in Formula A below:
[0004]
[0005] CN1022566C discloses a method for synthesizing paliperidone, comprising: reacting compound B with compound SM2 in an organic solvent under alkaline conditions to obtain:
[0006]
[0007] In this method, compound SM2, impurity E, impurity F and impurity I are the main impurities in the synthesis process:
[0008]
[0009] Among them, impurity E and impurity F are both process impurities and degradation impurities. The structure of impurity E is very similar to paliperidone and it is difficult to remove it by a simple solvent refining method. SM2 is an unreacted raw material, and impurity I is an impurity introduced by the raw material.
[0010] Impurities in paliperidone or any active pharmaceutical ingredient (API) are undesirable and, in extreme cases, may even endanger the health of patients treated with drugs containing the API. In addition, the purity of industrially produced APIs is also a necessary condition for medical use, and impurities introduced during industrial production must be limited to very small amounts and preferably substantially absent. For example, the ICH guidelines for API manufacturers recommend impurity levels within specified limits, i.e., any single impurity is less than 0.1% and the total amount of impurities is less than 0.5%.
[0011] CN104418855A discloses a method for preparing high-purity paliperidone, which comprises reacting 3-(2-chloroethyl)-9-hydroxy-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one with N-alkylated 6-fluoro-3-(piperidin-4-yl)-1,2-benzisoxazole hydrochloride in the presence of a base to prepare crude paliperidone, and then recrystallizing the crude paliperidone with an acetonitrile / water solvent (4:1) to form paliperidone oxalate, and then preparing pure paliperidone. The method is complicated to operate, and due to different process routes, does not involve a method for controlling the content of impurities F and impurity I. In addition, the content of impurity E in the purified paliperidone is an upper limit.
[0012] CN104140423A discloses a method for reducing and refining with sodium borohydride, wherein sodium borohydride is added to a two-phase system of dichloromethane and water, and after the reduction is completed, the aqueous phase is separated, the organic phase is concentrated to dryness, the concentrate is recrystallized with N,N-dimethylformamide, and then slurried with N,N-dimethylformamide under vacuum conditions, and finally recrystallized with ethanol to obtain paliperidone I crystal form; the process has a long process step and uses a toxic reagent N,N-dimethylformamide, which is not suitable for industrial production.
[0013] WO2012164242 adopts the method of adding a catalytic amount of a reducing agent to the reaction system to suppress the generation of oxidative impurities E while preparing paliperidone. However, low-boiling-point and highly toxic dichloromethane is used in the refining of the crude product, which is not suitable for industrial production. In addition, there is a risk of increasing the content of impurity E during the refining process. The use of a reducing agent can also cause the residue on ignition, inorganic salts, etc. in the paliperidone raw material to exceed the standard, which cannot meet the risks specified in the pharmacopoeia.
[0014] WO2008021342 discloses a method for preparing multiple crystalline forms and amorphous forms of paliperidone including paliperidone crystal form II, wherein paliperidone is synthesized by reacting CMHTP and FPBI in DMF, then extracted with dichloromethane, and crystallized with acetonitrile to obtain paliperidone with a yield of 58% and a purity of 90%, which is a mixed crystal of paliperidone crystal form I and crystal form V, and paliperidone is heated and refluxed with ethanol as a solvent, and then cooled and crystallized. The method is cumbersome to operate, has a low reaction yield, many by-products, and a low purity of the crude product, which is not conducive to subsequent purification; the purity of the product obtained by crystallization is low, and the single impurity exceeds 0.1%.
[0015] There is also prior art that discloses the use of tetrahydrofuran as a crystallization solvent to purify crude paliperidone. Although tetrahydrofuran helps to reduce the generation of oxidative impurities E, tetrahydrofuran belongs to the second category of solvents, is highly toxic, and is not easy to remove. Its use is restricted in drug production, and the solvent residue limit requirement is low (the limit is only 720 ppm), which can easily lead to excessive solvent residues, and is not suitable for use in the final refining step of the raw material.
[0016] As APIs for human use, the pharmacopoeias, drug registration management methods, ICH and other laws and regulations of various countries have strict requirements on their quality standards. Only by combining the endpoint control of quality standards with the process control of production can the quality of products be fully controlled. APIs usually consider the effects of starting materials and reagents, preparation intermediates and side reaction products, and organic solvents used in the preparation process on the quality of the final product. Among them, organic and inorganic impurities and residual solvents are key controls that need to be controlled in the quality research of APIs, and other detection items such as ignition residue are also included.
[0017] At present, there is still a lack of methods for reducing the content of process impurities SM2, impurity E, impurity F and impurity I in paliperidone raw materials through process optimization while improving the yield of paliperidone, and meeting the requirements of industrial production and pharmaceutical laws and regulations such as the safety of the solvent used, the solvent residue and the residue on ignition within the limit. Therefore, it is of great practical significance to develop a preparation method for high-purity paliperidone that is suitable for industrial production and can meet clinical and commercial needs. Summary of the invention
[0018] In order to solve the above problems existing in the prior art, the present invention provides a method for reducing impurities of paliperidone, which has the advantages of simple operation, wide safety range of the solvent used, high reaction yield, high product purity, and the ability to simultaneously reduce the contents of multiple process impurities and / or degradation impurities and / or hydrolysis impurities in the raw material drug, and avoid the introduction of reducing agents, avoid excessive ignition residues and sulfate residues that fail to meet the requirements specified in the pharmacopoeia, and the like.
[0019] In a first aspect of the present invention, a method for preparing paliperidone is provided, the method comprising reacting compound B with compound SM2 to prepare paliperidone (compound A):
[0020]
[0021] in,
[0022] 1) Compound B reacts with compound SM2 under alkaline conditions to prepare compound A;
[0023] 2) adding a neutralization step after the reaction is completed;
[0024] 3) After the neutralization reaction, the wet product containing paliperidone is separated and crystallized using an organic solvent I-water to obtain a pure paliperidone product.
[0025] Another aspect of the present invention provides a method for reducing impurities in paliperidone raw materials, the method comprising reacting compound B with compound SM2 to prepare paliperidone:
[0026]
[0027] in,
[0028] 1) Compound B reacts with compound SM2 under alkaline conditions to prepare compound A;
[0029] 2) adding a neutralization step after the reaction is completed;
[0030] 3) After the neutralization reaction, the wet product containing paliperidone is separated and crystallized using an organic solvent I-water to obtain a pure paliperidone product.
[0031] Preferably, the impurities include one or more of SM2, impurity F, impurity E and impurity I, wherein the structures of impurities SM2, impurity F, impurity E and impurity I are as follows:
[0032]
[0033] In a preferred embodiment, in the above method, the step 1) comprises: compound B and compound SM2 are reacted in an organic solvent II under alkaline conditions and heated to 60-90° C. under nitrogen protection; after the reaction, the temperature is lowered to 0-30° C., preferably 10-20° C., stirred, filtered, and dried to obtain crude paliperidone I;
[0034] The nitrogen protection can be either continuous nitrogen flow into the reaction system during the reaction, or replacing the air in the reaction container with nitrogen before the reaction system is heated to 60-90° C. Preferably, the nitrogen protection is carried out by nitrogen replacement.
[0035] The organic solvent II is selected from one or more of acetonitrile, isopropanol, ethanol, and dichloromethane; preferably, the organic solvent II is selected from acetonitrile.
[0036] More preferably, the base is selected from one or more of sodium carbonate, potassium carbonate, sodium hydroxide and potassium hydroxide, and particularly preferably the base is sodium carbonate.
[0037] In a preferred embodiment of the present invention, in the above method, the step 1) comprises: compound B and compound SM2 are replaced with nitrogen in an organic solvent II under alkaline conditions, and heated to 60-90°C under nitrogen protection for reaction; after the reaction, the temperature is lowered to 0-30°C, preferably 10-20°C, stirred, filtered, and dried to obtain a crude paliperidone product I; the organic solvent II is at least one of acetonitrile, isopropanol, ethanol or dichloromethane, and the base is at least one of sodium carbonate and potassium carbonate.
[0038] In a preferred embodiment of the present invention, in the above method, the neutralization reaction in step 2) comprises adding the crude paliperidone I obtained in step 1) into water, then adjusting the pH of the system to 7-8, and stirring; more preferably, 1-10 mol / L hydrochloric acid is used to adjust the pH to 7-8.
[0039] The inventors unexpectedly found that adding a neutralization reaction step after the reaction can reduce the content of impurity F; further studies have found that adding the crude paliperidone I obtained in step 1) to water, then adjusting the pH of the system to 7-8, and stirring can significantly reduce the increase of impurity F. It is speculated that the increase of impurity F may be due to the fact that the increase of impurity F is relatively fast under alkaline conditions, and adding a neutralization reaction step inhibits the increase of impurity F.
[0040] Therefore, in a more preferred embodiment of the present invention, the above method, the step 2) comprises adding the crude paliperidone product I obtained after the reaction to water, then adding 1-10 mol / L hydrochloric acid to adjust the pH to 7-8, heating and stirring, filtering, and collecting the wet product. Preferably, the heating temperature is 20-50°C, such as 25-30°C, 30-35°C, 35-45°C or 45-50°C and any temperature therebetween, more preferably 30-50°C.
[0041] In a preferred embodiment, in the above method, the crystallization process in step 3) comprises adding the wet paliperidone obtained after the neutralization reaction step to an organic solvent I-water system, heating and stirring, and then cooling and crystallizing to obtain pure paliperidone; preferably, the heating temperature is 50-75°C; further preferably, the cooling and crystallization is to reduce the temperature to 0-20°C, preferably 5-15°C.
[0042] In a preferred embodiment, in the above method, the crystallization process in step 3) can be repeated once or multiple times, for example, once, twice or three times.
[0043] In a preferred embodiment, in the above method, in the crystallization process of step 3), the heating temperature is 50-75°C, such as 50-60°C, 55-65°C, 60-70°C, or 65-75°C, etc. and any value therebetween. In a preferred embodiment, in the crystallization process of step 3), the cooling temperature is 0-20°C, such as 5-20°C, 5-15°C, 5-10°C, or 10-15°C and any value therebetween, preferably 5-15°C.
[0044] In a preferred embodiment, in the above method, in the crystallization process of step 3), the cooling can be directly reducing the temperature to 0-20°C (preferably 5-15°C), or can be carried out by cooling in stages to 0-20°C (preferably 5-15°C).
[0045] The staged cooling means that the process from the initial temperature to the final temperature includes at least one intermediate temperature, that is, the initial temperature is first reduced to the intermediate temperature, stirred for a period of time, and then continued to be reduced to the final temperature; for example, in one embodiment, the staged cooling includes reducing the temperature from 50-75°C to 0-20°C once, twice, three times, or four times; preferably, the cooling gradient is 5-30°C, such as 1-5°C, 5-10°C, 10-15°C, 10-20°C, 10-25°C, 10-30°C, 15-20°C, 15-25°C, 15-30°C, 20-25°C, etc. and any value therebetween, more preferably, the cooling gradient is 10-25°C each time; further preferably, stirring is performed for 0.1-10h after each cooling, preferably 0.3-5h, more preferably 0.3-3h;
[0046] In a preferred embodiment, in the above method, in the crystallization process of step 3), the cooling and crystallization includes first lowering the temperature to 30-50°C and continuing to stir, and / or lowering the temperature to 15-25°C and continuing to stir, and finally lowering the temperature to 5-15°C and continuing to stir and crystallize, and stirring for 0.1-10 hours, preferably 0.3-5 hours, and more preferably 0.3-3 hours after each cooling.
[0047] In a preferred embodiment, in the above method, in step 3) the crystallization process, the cooling comprises directly lowering the temperature from 50-75°C to 0-20°C, preferably 5-15°C, followed by stirring and filtering.
[0048] In a preferred embodiment, in the above method, the crystallization process in step 3) is carried out under nitrogen protection, and the nitrogen protection does not include continuously introducing a nitrogen flow into the reaction vessel during the reaction; further preferably, the nitrogen protection is to replace the air in the reaction vessel with nitrogen before heating.
[0049] In a preferred embodiment, in the above method, the crystallization process in step 3) comprises adding the wet paliperidone obtained in the neutralization reaction step to an organic solvent I-water system, replacing with nitrogen, heating and stirring under nitrogen protection, and then cooling and crystallizing to obtain pure paliperidone.
[0050] The inventors found that the step 3) adding the paliperidone wet product to the organic solvent I-water system, replacing the air in the reaction vessel with nitrogen, heating the temperature to 50-75°C with stirring under nitrogen protection, cooling for crystallization, filtering, and drying to obtain the paliperidone pure product can significantly inhibit the increase of impurity F in the paliperidone pure product. However, if the nitrogen replacement is replaced by continuously passing a nitrogen flow into the reaction vessel during the crystallization process, it will lead to the increase of impurity F in the paliperidone pure product. Therefore, in a preferred embodiment of the present invention, the nitrogen protection does not include continuously passing nitrogen into the reaction system during the reaction process.
[0051] In a preferred embodiment of the present invention, in the above method, the crystallization process in step 3) comprises adding the wet paliperidone obtained in the neutralization reaction step to an organic solvent I-water system, replacing with nitrogen, heating to 50-75°C with stirring under nitrogen protection, then cooling to 0-20°C (preferably 5-15°C), stirring for crystallization, and filtering to obtain pure paliperidone.
[0052] In a preferred embodiment, in the above method, optionally, the crystallization in step 3) further comprises adding seed crystals to the reaction system to obtain a pure paliperidone of a specific crystalline form.
[0053] In a preferred embodiment of the present invention, the organic solvent I is selected from one or more of ethanol, acetone, methanol, and acetonitrile. Preferably, the organic solvent I is selected from one or a mixture of ethanol and acetone.
[0054] In a preferred embodiment of the present invention, the weight ratio of the organic solvent I to water in step 3) is 1 to 5:1, preferably 1 to 3:1, such as 1 to 2:1 or 2 to 3:1, and any value therebetween.
[0055] Further preferably, the weight ratio of the organic solvent I to the paliperidone wet product in step 3) is about 5 to 20:1, such as 5:1, 10:1, 15:1, 16:1, 17:1, 18:1, 19:1 or 20:1, and any value between two numbers, preferably about 8 to 20:1. The paliperidone wet product refers to paliperidone obtained by filtering and drying after the reaction is completed, and optionally with or without drying. In a preferred embodiment, based on the weight of the starting material SM2, the weight ratio of the organic solvent I to SM2 in step 3) is 10 to 30:1, such as 15 to 25:1, 20 to 25:1, and the like. In a preferred embodiment, in the method of the present invention, the reaction is terminated when the content of the compound SM2 is controlled to be ≤1.0% during the reaction in step 1); preferably, the reaction is terminated when the content (%) of SM2 in the reaction system is ≤1.0% by HPLC.
[0056] In a specific embodiment of the present invention, a method for preparing paliperidone or a method for reducing impurities in a paliperidone raw material is provided, the method comprising reacting compound B with compound SM2 to prepare paliperidone:
[0057]
[0058] The impurities are selected from one or more of SM2, impurity F, impurity E and impurities of the following structure:
[0059]
[0060] in,
[0061] 1) Compound B and compound SM2 are reacted in an organic solvent II under alkaline conditions and heated to 60-90° C. under nitrogen protection; the SM2 content (%) in the reaction system is detected by HPLC to be ≤1.0%, and then the temperature is lowered to 0-30° C., preferably 10-20° C., stirred, filtered, and dried to obtain a crude paliperidone product I; wherein the nitrogen protection can be either continuous introduction of nitrogen flow into the reaction system during the reaction, or introduction of nitrogen into the reaction container before heating to 60-90° C. to replace the air in the reaction container;
[0062] 2) adding the crude paliperidone I obtained in step 1) into water, then adding hydrochloric acid to adjust the pH to 7-8, heating and stirring, filtering, and collecting the wet product; preferably, the heating temperature is 30-50° C.; further preferably, the concentration of hydrochloric acid used to adjust the pH is 1-10 mol / L, such as 4-6 mol / L;
[0063] 3) adding the wet product obtained in step 2) into an organic solvent I-water system for crystallization to obtain pure paliperidone.
[0064] Further preferably, step 3) comprises adding the paliperidone wet product to an organic solvent I-water system, heating to 50-75° C. with stirring, cooling to 5-15° C. for crystallization, filtering, and drying to obtain a pure paliperidone product;
[0065] Optionally, the method further comprises repeating step 3) one or more times.
[0066] Further preferably, the crystallization process in step 3) is carried out under nitrogen protection conditions, and preferably the nitrogen protection does not include continuously introducing a nitrogen flow into the reaction system; more preferably, the nitrogen protection is to introduce nitrogen into the reaction vessel before heating to 50-75°C to replace the air in the reaction vessel.
[0067] Further preferably, the organic solvent II is selected from one or more of acetonitrile, isopropanol, ethanol, and dichloromethane; more preferably, the organic solvent II is selected from acetonitrile.
[0068] Further preferably, the organic solvent I is selected from one or more of ethanol, acetone, methanol, and acetonitrile; more preferably, the organic solvent I is selected from one or a mixture of ethanol and acetone.
[0069] According to the method of the present invention, the molar ratio of the base to compound B in step 1) is 1 to 3:1, such as 1:1, 1:2, or 1:3 and any value therebetween; preferably, the base is selected from one or more of sodium carbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide; further preferably, the molar ratio of compound B to compound SM2 in step 1) is 0.8 to 1.2:1, such as 0.8:1, 1:1, or 1.2:1 and any value therebetween;
[0070] Further preferably, the molar ratio of the organic solvent I to water in step 3) is 0.5-2:1, preferably 1-1.5:1; further preferably, the weight ratio of the organic solvent I to water in step 3) is 1-3:1, such as 1:1, 1.5:1, 2:, 2.5:1 or 3:1, and values between any two values.
[0071] More preferably, in step 3), the weight ratio of the organic solvent I to the paliperidone wet product is about 5 to 20:1, preferably about 8 to 15:1.
[0072] The method provided by the present invention can convert the process impurity SM2 into impurity I by crystallizing and purifying the crude paliperidone product using an ethanol-water system, and then remove the impurity I by heating, stirring, and filtering, thereby achieving the purpose of removing the impurity SM2 and the impurity I at the same time. However, the inventors also found that when ethanol-water is used as a crystallization solvent to purify the crude paliperidone product, the content of impurity F will increase. It is speculated that under the stirring conditions of ethanol-water / 50-75°C, paliperidone may be hydrolyzed into impurity F, and the reaction formulas are as follows:
[0073]
[0074]
[0075] In order to control the contents of impurities SM2, I, E and F in the finished product of paliperidone so as to meet the requirements of relevant laws and regulations on the quality standards of raw materials in the pharmaceutical field, the inventors have conducted a large number of experimental studies and explorations, and finally found that adding a neutralization reaction step before the crystallization purification step and using nitrogen replacement during the crystallization process can effectively inhibit the increase of impurities E and F, and remove impurities SM2 and I at the same time. At the same time, by adjusting the heating temperature and heating time during the crystallization process, the generation of degradation impurity E can be reduced.
[0076] In a preferred embodiment of the present invention, the content of the impurity SM2 in the paliperidone raw material prepared by the method is not higher than 0.05%, preferably, not higher than 0.04%, more preferably not higher than 0.01%, calculated by HPLC peak area percentage; and / or,
[0077] The content of impurity E is not higher than 0.08%, preferably not higher than 0.07%, more preferably not higher than 0.06%; and / or,
[0078] The content of impurity F is not higher than 0.04%, preferably not higher than 0.03%, more preferably not higher than 0.02%; and / or,
[0079] The content of impurity I is not higher than 0.03%, preferably not higher than 0.02%, and more preferably not higher than 0.01%.
[0080] Further preferably, calculated by HPLC peak area percentage, the content of impurity SM2 in the paliperidone raw material prepared by the method is not higher than 0.01%, the content of impurity E is not higher than 0.08%, the content of impurity F is not higher than 0.02% and the content of impurity I is not higher than 0.01%.
[0081] The "crude paliperidone" of the present invention refers to paliperidone containing unreacted starting materials, reaction by-products, side reaction products and / or degradation products generally referred to as impurities.
[0082] The "pure paliperidone" described in the present invention refers to paliperidone containing less than 0.1% of each single impurity; preferably, less than about 0.05% and less than 0.3% of the total amount of impurities, most preferably less than 0.22%.
[0083] Purity was checked by HPLC and expressed as area percentage as shown in the attached HPLC chromatogram.
[0084] The present invention optimizes the synthesis process conditions and post-treatment method for preparing paliperidone by reacting compound B with compound SM2, which can not only significantly improve the reaction yield and purity of paliperidone, but also simultaneously reduce the contents of multiple process impurities and degradation impurities. In addition, the solvent used in the method has a high safety range and can meet the requirements of commercial large-scale production applications and the requirements of relevant laws and regulations such as the "Drug Registration Management Measures", the "Pharmacopoeia" and the ICH on the quality standards of raw materials.
[0085] Specifically, the post-treatment solvent of the present invention uses water and / or ethanol and / or acetone, and in particular, ethanol is used as the organic solvent for crystallization. On the one hand, the solvent has a large safety range, and on the other hand, the solvent is easy to remove, and there is no risk of excessive solvent residue. The inventors found that in the process of preparing paliperidone by reacting compound B with compound SM2, nitrogen protection is used, and by selecting a suitable organic solvent I-water as the crystallization solvent, the content of degradation impurity E can be significantly suppressed by nitrogen replacement and simultaneous control of heating temperature and time during the crystallization process; the inventors also unexpectedly found that adding nitrogen flow for protection during the crystallization process will promote the increase of impurity F. In this regard, the inventors conducted a large number of experimental studies and finally adopted nitrogen protection for the crystallization process by nitrogen replacement, which can not only reduce the content of impurity E, but also help to suppress the growth of impurity F; further, in the reaction After the reaction is completed and before crystallization, a neutralization reaction step is added to further inhibit the growth of impurity F; in addition, during the reaction, by monitoring the content of the raw material SM2, the reaction is terminated when the content of SM2 is ≤1.0% during the reaction, and then a suitable crystallization temperature and crystallization solvent (organic solvent I-water) are selected. During the crystallization process, impurity SM2 is converted into impurity I, and impurity I is removed by crystallization filtration; the paliperidone prepared by the method of the present invention has a high yield and purity (for example, the yield is as high as 85% or more, and the purity is not less than 99.7%), and the impurity content of each process is significantly lower than 0.1%, and the total impurity is lower than 0.3%. In addition, the method provided by the present invention avoids the use of reducing agents such as hydrosulfite, surfactants, etc. during the reaction process and purification process, thereby avoiding the introduction of heavy metals, inorganic salts, etc. into the raw materials. BRIEF DESCRIPTION OF THE DRAWINGS
[0086] Figure 1 The HPLC spectrum of the paliperidone wet product obtained after the neutralization reaction step according to the method of Example 1 is shown, wherein the peak at RT=22.233min is the peak of paliperidone, the peak at RT=6.110min is the peak of impurity I, the peak at RT=17.153min is the peak of impurity SM2, the peak at RT=20.717min is the peak of impurity E, and the peak at RT=24.700min is the peak of impurity F;
[0087] Figure 2 The HPLC spectrum of the paliperidone bulk drug prepared by crystallization according to the method of Example 1 is shown, wherein the peak at RT=22.210 min is the peak of paliperidone, the peak at RT=17.150 min is the peak of impurity SM2, the peak at RT=20.707 min is the peak of impurity E, and the peak at RT=24.703 min is the peak of impurity F;
[0088] Figure 3The HPLC spectrum of the paliperidone bulk drug prepared by crystallization according to the method of Example 2 is shown, wherein the peak at RT=22.203min is the peak of paliperidone, the peak at RT=20.737min is the peak of impurity E, and the peak at RT=24.680min is the peak of impurity F. Specific embodiments
[0089] The technical scheme and beneficial effects of the present invention are further described below by way of examples, but the present invention is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the instructions of the products.
[0090] First, the present invention provides a method for reducing impurities in a paliperidone raw material, the method comprising reacting a compound B with a compound SM2 to prepare paliperidone:
[0091]
[0092] The impurities include one or more of SM2, impurity F, impurity E and impurity I, wherein the structures of impurities SM2, impurity F, impurity E and impurity I are as follows:
[0093]
[0094] Secondly, the present invention also provides a method for preparing paliperidone, the method comprising reacting compound B with compound SM2 to prepare paliperidone:
[0095]
[0096] in,
[0097] 1) Compound B and compound SM2 are reacted in an organic solvent II under alkaline conditions and heated to 60-90° C. (preferably 65-75° C.) under nitrogen protection; the SM2 content (%) in the reaction system is detected by HPLC to be ≤1.0%, and then the temperature is lowered by 0-30° C., stirred, filtered, and dried to obtain a crude paliperidone product I;
[0098] Further preferably, the method comprises adding compound B and compound SM2 to an organic solvent II, then adding a base and KI, replacing with nitrogen, heating to 65-75° C. under nitrogen protection and stirring to react, HPLC detecting the SM2 content (%) in the reaction system to be ≤1.0%, then cooling to 0-30° C., stirring, filtering, optionally, eluting the wet product with an organic solvent II, and then drying to obtain a crude paliperidone product I;
[0099] In the above method, the base is selected from one or more of sodium carbonate, potassium carbonate, sodium hydroxide, and potassium hydroxide; the molar ratio of the base to compound B is 1 to 3:1, such as 1:1, 1:2, or 1:3 and any value therebetween;
[0100] The organic solvent II is selected from acetonitrile, isopropanol, ethanol, and dichloromethane; preferably, the organic solvent II is selected from acetonitrile;
[0101] The molar ratio of compound B to compound SM2 is 0.8 to 1.2:1, such as 0.8:1, 1:1, or 1.2:1 and any value therebetween;
[0102] The reaction system also includes KI, and the molar ratio of compound B to KI is preferably 8 to 12:1, such as 9 to 10:1, 10 to 11:1, etc.;
[0103] 2) adding a neutralization step after the reaction is completed, that is, adding the crude paliperidone I obtained in step 1) to water, then adjusting the pH to 7-8, heating and stirring, filtering, and collecting the wet product;
[0104] Preferably, the heating temperature is 20 to 50°C, more preferably 30 to 50°C;
[0105] The pH is adjusted to 7-8, preferably using 1-10 mol / L hydrochloric acid, more preferably the concentration of hydrochloric acid is 4-8 mol / L, more preferably 5-7 mol / L;
[0106] Further preferably, during the pH adjustment process, the temperature of the solution system does not exceed 35°C, preferably room temperature, such as controlling the temperature at 25±5°C;
[0107] The heating and stirring time can be 0.01 to 20 hours, such as 0.1 to 1 hour, 0.2 to 2 hours, 0.3 to 3 hours, 0.1 to 5 hours or 0.5 to 1 hour, etc.;
[0108] 3) After the neutralization reaction, separating the wet product containing paliperidone, and crystallizing it with an organic solvent (I)-water to obtain a pure paliperidone;
[0109] Further preferably, the crystallization step comprises:
[0110] The paliperidone wet product is added to an organic solvent I-water system, replaced with nitrogen, heated and stirred, then cooled for crystallization, filtered, and dried to obtain the paliperidone pure product;
[0111] Wherein, the heating temperature is 50-75°C, preferably 65-75°C; the cooling temperature is 5-15°C;
[0112] Further preferably, the stirring time of heating to 50-75° C. in step 3) is 0.1-10 h, such as 0.1-10 h, 1-5 h, 0.5-3 h, 1-6 h, 2-8 h, 2-5 h, or 1-3 h, and any value therebetween;
[0113] The stirring time of cooling to 5-15°C is 0.01-10h, such as 0.1-10h, 0.5-5h, 0.5-3h, 1-5h, 2-6h, 3-8h, or 2-4h and any value therebetween;
[0114] The organic solvent I is selected from at least one of ethanol and acetone;
[0115] Further preferably, the drying temperature is 50 to 70°C, for example 55 to 65°C;
[0116] More preferably, the molar ratio of the organic solvent I to water is 0.5 to 2:1, preferably 1 to 1.5:1;
[0117] More preferably, the weight ratio of the organic solvent to the paliperidone wet product is about 1 to 50:1, preferably 5 to 20:1, and more preferably 8 to 15:1.
[0118] Optionally, the method further comprises repeating step 3) one or more times.
[0119] In another embodiment of the present invention, the cooling in step 3) is cooling in stages to 5-15°C; the staged cooling includes cooling the temperature from 50-75°C to 5-15°C once, twice, three times, or four times, preferably, the gradient of each cooling is 5-30°C, more preferably 10-25°C; further preferably, stirring for 0.1-10h, preferably 0.3-5h, more preferably 0.3-3h after each cooling; in a preferred embodiment, the staged cooling includes: first lowering the temperature to 30-50°C and continuing to stir, and / or lowering the temperature to 15-25°C and continuing to stir, and / or lowering the temperature to 5-15°C and continuing to stir for crystallization.
[0120] Further preferably, the stepwise cooling includes first cooling the temperature to 30-55°C, preferably 30-40°C, optionally adding seed crystals, continuing stirring, and then cooling to 5-15°C once or multiple times, stirring, crystallizing, filtering, and drying to obtain pure paliperidone;
[0121] Further preferably, the stirring time for heating to 50-75°C is 0.01-10h, for example, 0.5-5h, 0.5-3h, 1-6h, 2-8h, 2-5h, or 0.1-10h, etc. and any value therebetween; the stirring time for cooling to 30-55°C and continuing is 0.1-10h, for example, 0.5-5h, 0.5-3h, 1-6h, 2-8h, or 2-5h, etc. and any value therebetween; the stirring time for cooling to 5-15°C is 0.01-10h, for example, 0.1-10h, 0.5-5h, 0.5-3h, 1-5h, 2-6h, 3-8h, or 2-4h, etc. and any value therebetween.
[0122] The above method can reduce one or more impurities in the paliperidone raw material, wherein the impurities are process impurities and / or degradation impurities and / or hydrolysis impurities; further, the impurities include one or more of SM2, impurity F, impurity E and impurity I, wherein the structures of the impurities SM2, impurity F, impurity E and impurity I are as follows:
[0123]
[0124] Particularly preferably, the method for reducing impurities in paliperidone raw materials can simultaneously reduce the contents of impurity SM2, impurity F, impurity E and impurity I in the paliperidone raw materials.
[0125] Further preferably, the content of impurity SM2 in the paliperidone raw material prepared by the above method is not higher than 0.05%, preferably, not higher than 0.04%, more preferably not higher than 0.01%, calculated by HPLC peak area percentage; and / or,
[0126] The content of impurity E is not higher than 0.08%, preferably not higher than 0.07%, more preferably not higher than 0.06%; and / or,
[0127] The content of impurity F is not higher than 0.04%, preferably not higher than 0.03%, more preferably not higher than 0.02%; and / or,
[0128] The content of impurity I is not higher than 0.03%, preferably not higher than 0.02%, and more preferably not higher than 0.01%.
[0129] Further preferably, calculated by HPLC peak area percentage, in the paliperidone raw material prepared by the above method, the content of impurity SM2 is not higher than 0.05%, the content of impurity E is not higher than 0.08%, the content of impurity F is not higher than 0.03% and the content of impurity I is not higher than 0.01%.
[0130] The technical solutions and beneficial effects of the present invention are explained in more detail below in conjunction with specific embodiments.
[0131] HPLC detection method:
[0132] Column & Packing: Waters Xbridge C18, 4.6×150mm, 3.5μm or chromatographic column with equivalent performance;
[0133] Eluent A: 100 mM ammonium formate aqueous solution (pH 4.2);
[0134] Eluent B: acetonitrile-methanol-tetrahydrofuran (600:200:200);
[0135] Elution method:
[0136]
[0137] Flow rate: 0.8ml / min;
[0138] Injection volume: 10 μl;
[0139] Detection wavelength: 275nm;
[0140] Column temperature: 30 °C;
[0141] Diluent: methanol-water (1:1)
[0142] Preparation of sample solution: Take about 20 mg of the test sample (paliperidone raw material) and put it into a 25 ml volumetric flask. Add 10 ml of methanol and ultrasonically dissolve it. Then add 10 ml of water. After cooling to room temperature, dilute to the scale with diluent and shake well.
[0143] Calculation method: area normalization method.
[0144] Example 1: Preparation of Paliperidone
[0145]
[0146] 1) 47.0 kg of acetonitrile was pumped into a 100 L reaction tank, stirring was started, 4.0 kg of compound B, 3.5 kg of compound SM2, 3.8 kg of anhydrous sodium carbonate, 0.25 kg of potassium iodide were added, nitrogen was replaced, heated to 70±5° C. under nitrogen protection and stirred, and monitored by HPLC (Spec. SM2 content ≤1.0%). After the reaction was completed, the temperature was lowered to 15±5° C., stirred for about 30 minutes, filtered, the wet product was eluted with acetonitrile, and dried to obtain crude paliperidone I for standby use.
[0147] 2) Add 40.0 kg of water to a 100 L reaction tank, add the above crude paliperidone I, control the temperature to 25±5°C, stir, add 6 mol / L hydrochloric acid to adjust the pH to 7-8, heat to 40±5°C and stir for about 30 minutes, filter, rinse with water, spin dry, and collect the wet product for later use. Figure 1As shown, the purity of the wet product measured by HPLC area normalization method is 99.11%, impurity I: 0.036%, impurity SM2: 0.38%, impurity E content: 0.038%, impurity F: 0.03%.
[0148] 3) Add 68.5 kg of ethanol and 28.0 kg of water to a 200 L reaction tank, stir, add the above wet product, replace with nitrogen, heat to 70±5°C, keep warm and stir for 2 hours, cool to 10±5°C, stir for 3 hours, filter, rinse the wet product with ethanol, and dry in vacuo at 60±5°C to obtain 5.15 kg of pure paliperidone. The yield is 83.9% (based on SM2). Figure 2 As shown, the purity of paliperidone measured by HPLC area normalization method was: 99.73%, SM2: 0.034%; impurity E: 0.058%; impurity F: 0.028%; impurity I: not detected.
[0149] Example 2: Preparation of Paliperidone
[0150] Paliperidone wet product was prepared by the same method as steps 1) and 2) of Example 1; 90.0 kg of ethanol and 37.8 kg of water were added to a 200 L reaction tank (1), stirring was started, 5.0 kg of paliperidone wet product was added, nitrogen replacement was performed, the mixture was heated to 70±5° C., stirred for 30 minutes, cooled to 50±5° C., the material was filtered into a 200 L reaction tank (2) and maintained at 35±5° C., 25 g of paliperidone crystal form II was added as a seed crystal, stirred for 3 hours, cooled to 20±5° C., stirred for 3 hours, cooled to 10±5° C., stirred for 3 hours, filtered, and dried in vacuo at 60±5° C. to obtain 4.26 kg of paliperidone crystal form II with a yield of 85.2%, as shown in FIG. Figure 3 As shown, the purity of Form II paliperidone measured by HPLC area normalization method was 99.81%; SM2 was not detected, impurity E: 0.077%, impurity F: 0.018%; impurity I: not detected.
[0151] The paliperidone crystalline form II is the same as the crystalline form II disclosed in patent WO2008021342A2, and its XRPD can be found in Figure 6 of WO2008021342A2.
[0152] Example 3: Effect of crystallization conditions on the content of impurity SM2 and impurity I
[0153] Paliperidone was prepared according to the method of steps 1 to 3) of Example 1, and the contents of impurity SM2 and impurity I were detected by HPLC according to the sampling points in Table 3.1. The detection process and the detection results are shown in Table 3.1:
[0154] Table 3.1: Conversion and removal of impurities SM2 and I during the process
[0155]
[0156] It can be seen from the sampling test results of the reaction process in Table 1 that by adopting the method provided by the present invention, by controlling the crystallization solution system and the crystallization temperature, SM2 can be effectively converted into impurity I and removed.
[0157] Example 4: Effect of the Neutralization Reaction Step on Impurity E
[0158] Example 4A After preparing crude paliperidone I by the method of step 1) of Example 1, directly crystallize by the method of step 3) without going through the neutralization step of step 2) to prepare pure paliperidone; and in step 3), the crystallization system is heated to 70±5° C. and stirred for 2 hours before taking samples for HPLC detection;
[0159] Example 4B Pure paliperidone was prepared by the same method as steps 1), 2) and 3) of Example 1; and in step 3), the crystallization system was heated to 70±5° C. and stirred for 2 h and after filtration, the product was sampled for HPLC detection;
[0160] The test results are shown in Table 4.1 below.
[0161] Table 4.1: Effect of the neutralization step on impurity E
[0162]
[0163] It can be seen from the above test results that after the reaction is completed, adding a neutralization reaction step can inhibit the increase of the impurity E content in the subsequent purification process.
[0164] Example 5: Effect of nitrogen flow and nitrogen replacement on impurities F and E during crystallization in step 3)
[0165] Example 5A: Pure paliperidone was prepared according to a method similar to step 1), step 2) and step 3) of Example 1, wherein in step 3), the crystallization system was heated to 70±5°C, the heat preservation and stirring time was extended from 2h to 4h, and samples were taken before heating to 70±5°C and stirring for 1h, 2h, 3h and 4h, respectively, for HPLC detection;
[0166] Example 5B: The same method as Example 5A was used, except that the nitrogen replacement of the crystallization system in step 3) of Example 5A was replaced by continuous nitrogen flow in the crystallization system, and the same method was used to take samples for HPLC detection before heating to 70±5°C and stirring for 1h, 2h, 3h and 4h;
[0167] Example 5C: The same method as Example 5A was used, except that the nitrogen replacement of the crystallization system in step 3) of Example 5A was removed, and nitrogen protection was not performed during the crystallization process. The same method was used to take samples for HPLC detection before heating to 70±5°C and stirring for 1h, 2h, 3h and 4h;
[0168] The test results of Examples 5A, 5B and 5C are shown in Table 5.1 below.
[0169] Table 5.1: Effect of nitrogen flow and nitrogen replacement on impurities F and E
[0170]
[0171] From the test results in Table 5.1, it can be seen that the use of nitrogen flow protection during the crystallization process will lead to a significant increase in the content of impurity F, that is, promote the hydrolysis of paliperidone. When crystallization is carried out in a nitrogen flow or nitrogen replacement atmosphere, the oxidized impurity E will increase slowly, with no obvious difference. However, in the production scale-up process, crystallization is carried out in an air atmosphere, and the impurity E increases significantly compared with nitrogen flow and nitrogen replacement.
[0172] Example 6: Effects of the reaction process and post-treatment process on impurity E
[0173] Paliperidone was prepared according to the method of step 1) of Example 1. During the reaction, a sample (sample ①) was taken for HPLC detection. The detection result showed that the content of SM2 was ≤1.0% and the content of impurity E was 0.11%. After the reaction was completed, the same method as step 1) of Example 1 was used for filtration and drying to obtain a crude paliperidone product I (sample ②). A sample was taken for HPLC detection. The detection result showed that the content of impurity E was 0.06%.
[0174] According to the method of step 2) of Example 1, the obtained crude paliperidone I was subjected to neutralization reaction, filtered, and a sample (sample ③) was taken for HPLC detection. The detection result showed that the content of impurity E was 0.04%;
[0175] The paliperidone wet product was slurried according to the method of step 3) of Example 1. After the crystallization system was heated to 70±5°C and stirred for 2h, a sample was taken for testing before the temperature was lowered (sample ④), and the obtained paliperidone pure product (sample ⑤) was tested by HPLC. The contents of impurity E were 0.09% and 0.06%, respectively.
[0176] The pure paliperidone was crystallized again according to the method of step 3) of Example 1. Samples were taken for detection before the crystallization system began to cool down for crystallization (sample ⑥). The pure paliperidone obtained after recrystallization (sample ⑦) was also subjected to HPLC detection. The detection results showed that the contents of impurity E were 0.14% and 0.08%, respectively.
[0177] Table 6.1 Changes of impurity E in various treatment processes
[0178]
[0179]
[0180] The results in Table 6.1 show that paliperidone is prone to produce degradation impurity E during the crystallization and purification process. The present invention can effectively control the paliperidone impurity E to a low content level (not exceeding 0.1%) by controlling the appropriate heating temperature and time, thereby meeting the requirements for the use of paliperidone as a raw material drug.
[0181] Comparative Example 1:
[0182] A 500 ml reaction bottle was added with 10.0 g of crude paliperidone (purity: 99.20%, impurity I: 0.03%, impurity SM2: 0.37%, impurity F: 0.02%, impurity E: 0.03%), 450 ml of anhydrous ethanol, 0.5 g of activated carbon, and nitrogen replacement. The mixture was heated to reflux and dissolved, hot filtered, cooled to 10-15 ° C with stirring, stirred for 2-3 hours, filtered, and the solid was washed with 10 ml of anhydrous ethanol, filtered, and dried in vacuo at 50-55 ° C to obtain 8.9 g of an off-white solid with a yield of 89% and a purity of 99.51%. Impurity I: 0.014%, impurity F: 0.019%, and impurity E: 0.23%; the test results showed that the content of impurity E increased significantly.
[0183] Comparative Example 2:
[0184] The inventors also tried to suppress the generation of impurity E by adding hydrosulfite during the reaction process, and purified the crude paliperidone by recrystallization. The specific method is as follows: 10.0 g of paliperidone (purity 99.20%, impurity I: 0.03%, impurity SM2: 0.37%, impurity F: 0.02%, impurity E: 0.03%), 45 ml of water, 135 ml of anhydrous ethanol, nitrogen replacement, heating to 75-80 ° C to dissolve, cooling to 60-65 ° C, adding 100 mg of activated carbon, stirring for 10 minutes, hot filtering, maintaining the temperature at 52 ° C, adding 100 ml of hydrosulfite, stirring for 30 minutes, slowly cooling to about 5 ° C and stirring for 2 hours, filtering, washing the solid with 10 ml of ethanol, and vacuum drying at 60 ° C to obtain 8.7 g of off-white solid, with a yield of 87%, a purity of 99.72%, and impurity E (0.022%);
[0185] Test Example: Sulfate Test
[0186] The paliperidone raw materials prepared by the methods of Example 1 and Comparative Example 2 of the present invention were respectively tested for sulfate. The detection method was inspected in accordance with the "Chinese Pharmacopoeia 2020 Edition" (General Rule 0802) and compared with the control solution (0.04%) made of 4.0 ml of standard potassium sulfate solution and the control solution (0.1%) made of 10.0 ml of standard potassium sulfate solution.
[0187] The test results show that the residual sulfate of the paliperidone raw material prepared by the method of Example 1 of the present invention is less than 0.04%; the residual sulfate of the paliperidone raw material prepared by the method of Comparative Example 2 is greater than 0.1%.
Claims
1. A method for preparing paliperidone, characterized in that: The method comprises reacting compound B with compound SM2 to prepare paliperidone, i.e., compound A: in, 1) Compound B reacts with compound SM2 under alkaline conditions; 2) adding a neutralization step after the reaction is completed; 3) After the neutralization reaction, the wet product containing paliperidone is separated and crystallized using an organic solvent I-water to obtain a pure paliperidone product.
2. The method according to claim 1, characterized in that Step 2) The neutralization reaction step comprises adding the crude paliperidone obtained by the reaction into water, and then adjusting the pH of the system to 7-8; Preferably, 1-10 mol / L hydrochloric acid is used to adjust the pH to 7-8; More preferably, the crude paliperidone obtained by the reaction is added to water, and then 1-10 mol / L hydrochloric acid is added to adjust the pH to 7-8, the mixture is heated and stirred, and filtered to collect the wet product.
3. The method according to claim 2, characterized in that The heating temperature is 20-50°C.
4. The method according to any one of claims 1 to 3, characterized in that Step 3) The crystallization process is protected by nitrogen, and the nitrogen protection does not include continuously introducing a nitrogen flow into the reaction vessel during the reaction. More preferably, the nitrogen protection includes replacing the air in the reaction device with nitrogen before the start of crystallization.
5. The method according to any one of claims 1 to 3, characterized in that: Step 1) During the reaction, the reaction is terminated when the content of compound SM2 is controlled to be ≤1.0%.
6. The method according to any one of claims 1 to 3, characterized in that Step 3) The crystallization comprises adding the paliperidone wet product obtained after the neutralization reaction into an organic solvent I-water system, heating and stirring, and then cooling and crystallizing to obtain a pure paliperidone product.
7. The method according to claim 6, characterized in that The heating temperature is 50-75° C.; more preferably, the crystallization step is repeated once or multiple times.
8. The method according to any one of claims 1 to 7, characterized in that: Step 3) The crystallization process includes: replacing the air in the reaction vessel with nitrogen before heating.
9. The method according to claim 1, characterized in that: The method comprises: 1) Compound B and compound SM2 are reacted in an organic solvent II under alkaline conditions and heated to 60-90° C. under nitrogen protection; the content of SM2 in the reaction system is detected by HPLC (%) ≤ 1.0%, and then the temperature is reduced to 0-30° C., stirred, filtered, and dried to obtain a crude paliperidone product I; 2) adding the crude paliperidone I obtained in step 1) into water, then adding hydrochloric acid to adjust the pH to 7-8, heating and stirring, filtering, and collecting the wet product; 3) adding the wet product obtained in step 2) into an organic solvent I-water system, replacing the air in the reaction device with nitrogen, and performing crystallization to obtain pure paliperidone.
10. The method according to any one of claims 1 to 9, characterized in that: Step 3) The crystallization process comprises: After the neutralization reaction, the separated paliperidone wet product is added to the organic solvent I-water system, the air in the reaction device is replaced by nitrogen, and then heated to 50-75°C with stirring, cooled to 5-15°C for crystallization, filtered and dried to obtain pure paliperidone.
11. The method according to any one of claims 1 to 10, characterized in that: The organic solvent I is selected from ethanol or acetone.
12. The method according to any one of claims 1 to 11, characterized in that: The content of impurity SM2 in the paliperidone raw material prepared by the method is calculated by HPLC peak area percentage and is not higher than 0.05%, preferably, not higher than 0.04%, and more preferably, not higher than 0.01%; and / or, The content of impurity E is not higher than 0.08%, preferably not higher than 0.07%, more preferably not higher than 0.06%; and / or, The content of impurity F is not higher than 0.04%, preferably not higher than 0.03%, more preferably not higher than 0.02%; and / or, The content of impurity I is not higher than 0.03%, preferably not higher than 0.02%, more preferably not higher than 0.01%; Further preferably, calculated by HPLC peak area percentage, the content of impurity SM2 in the paliperidone raw material prepared by the method is not higher than 0.01%, the content of impurity E is not higher than 0.08%, the content of impurity F is not higher than 0.02%, and the content of impurity I is not higher than 0.01%; The structures of impurity SM2, impurity F, impurity E and impurity I are as follows:
13. A method for reducing impurities in paliperidone raw materials, characterized in that: The method comprises applying the method according to any one of claims 1 to 11, wherein the impurities comprise one or more of SM2, impurity F, impurity E and impurity I, wherein the impurities SM2, impurity F, impurity E and impurity I have the following structures: Preferably, the impurities include SM2, impurity F, impurity E and impurity I at the same time.
